Does an Endometrial Cancer Diagnosis among Asymptomatic
Patients Improve Prognosis?

J 2022

Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?

VINKLEROVÁ, Petra, Petra OVESNÁ, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER et. al.

Basic information

Original name

Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?

Authors

VINKLEROVÁ, Petra (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Markéta BEDNAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Luboš MINÁŘ (203 Czech Republic, belonging to the institution), Michal FELSINGER (203 Czech Republic, belonging to the institution), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution) and Vít WEINBERGER (203 Czech Republic, guarantor, belonging to the institution)

Edition

Cancers, Basel, MDPI, 2022, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.200

RIV identification code

RIV/00216224:14110/22:00125126

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/cancers14010115

UT WoS

000741365900001

Keywords in English

endometrial cancer; postmenopausal bleeding; prognosis

Abstract

V originále

Background: Endometrial cancer is the most common gynecological malignancy in developed countries with no screening available. There is still a tendency to provide invasive bioptic verification in asymptomatic women with abnormal ultrasound findings to diagnose carcinoma in a preclinical phase; even though, it is not supported by European guidelines. Our goal was to determine DFS (disease-free survival), OS (overall survival), and DSS (disease-specific survival) differences between symptom-free and symptomatic (bleeding, or spotting) endometrial cancer patients with similar stage and tumor/clinical characteristics. Methods: All of our patients with endometrial cancer following surgical treatment between 2006 and 2019 were assessed, evaluating risk factors for recurrence and death while focusing on bleeding using univariable and multivariable analysis. Results: 625 patients meeting the inclusion criteria were divided into asymptomatic (n = 144, 23%) and symptomatic (n = 481, 77%) groups. The median follow-up was 3.6 years. Using univariable analysis, symptomatic patients had a three times higher risk of recurrence (HR 3.1 (95% Cl 1.24–7.77), p = 0.016). OS (HR 1.35 (0.84–2.19), p = 0.219) and DSS (HR 1.66 (0.64–4.28), p = 0.3) were slightly worse without reaching statistical significance. In our multivariable analysis, symptomatology was deemed completely insignificant in all monitored parameters (DFS: HR 2.03 (0.79–5.24), p = 0.144; OS: HR 0.72 (0.43–1.21), p = 0.216). Conclusions: The symptomatic endometrial cancer patients risk factor of earlier recurrence and death is insignificantly higher when compared with the asymptomatic cohort. However, multivariable analysis verifies that prognosis worsens with other clinically relevant parameters, not by symptomatology itself. In terms of survival outcome in EC patients, we recognized symptomatology as a non-significant marker for the patient’s prognosis.

Citovat

VINKLEROVÁ, Petra, Petra OVESNÁ, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Jitka HAUSNEROVÁ and Vít WEINBERGER. Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis? Cancers. Basel: MDPI, 2022, vol. 14, No 1, p. 1-11. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers14010115.

@article{1816307,
   author = {Vinklerová, Petra and Ovesná, Petra and Bednaříková, Markéta and Minář, Luboš and Felsinger, Michal and Hausnerová, Jitka and Weinberger, Vít},
   article_location = {Basel},
   article_number = {1},
   doi = {http://dx.doi.org/10.3390/cancers14010115},
   keywords = {endometrial cancer; postmenopausal bleeding; prognosis},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?},
   url = {https://www.mdpi.com/2072-6694/14/1/115},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 1816307
AU  - Vinklerová, Petra - Ovesná, Petra - Bednaříková, Markéta - Minář, Luboš - Felsinger, Michal - Hausnerová, Jitka - Weinberger, Vít
PY  - 2022
TI  - Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?
JF  - Cancers
VL  - 14
IS  - 1
SP  - 1-11
EP  - 1-11
PB  - MDPI
SN  - 20726694
KW  - endometrial cancer
KW  - postmenopausal bleeding
KW  - prognosis
UR  - https://www.mdpi.com/2072-6694/14/1/115
N2  - Background: Endometrial cancer is the most common gynecological malignancy in developed countries with no screening available. There is still a tendency to provide invasive bioptic verification in asymptomatic women with abnormal ultrasound findings to diagnose carcinoma in a preclinical phase; even though, it is not supported by European guidelines. Our goal was to determine DFS (disease-free survival), OS (overall survival), and DSS (disease-specific survival) differences between symptom-free and symptomatic (bleeding, or spotting) endometrial cancer patients with similar stage and tumor/clinical characteristics. Methods: All of our patients with endometrial cancer following surgical treatment between 2006 and 2019 were assessed, evaluating risk factors for recurrence and death while focusing on bleeding using univariable and multivariable analysis. Results: 625 patients meeting the inclusion criteria were divided into asymptomatic (n = 144, 23%) and symptomatic (n = 481, 77%) groups. The median follow-up was 3.6 years. Using univariable analysis, symptomatic patients had a three times higher risk of recurrence (HR 3.1 (95% Cl 1.24–7.77), p = 0.016). OS (HR 1.35 (0.84–2.19), p = 0.219) and DSS (HR 1.66 (0.64–4.28), p = 0.3) were slightly worse without reaching statistical significance. In our multivariable analysis, symptomatology was deemed completely insignificant in all monitored parameters (DFS: HR 2.03 (0.79–5.24), p = 0.144; OS: HR 0.72 (0.43–1.21), p = 0.216). Conclusions: The symptomatic endometrial cancer patients risk factor of earlier recurrence and death is insignificantly higher when compared with the asymptomatic cohort. However, multivariable analysis verifies that prognosis worsens with other clinically relevant parameters, not by symptomatology itself. In terms of survival outcome in EC patients, we recognized symptomatology as a non-significant marker for the patient’s prognosis.
ER  -

VINKLEROVÁ, Petra, Petra OVESNÁ, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Jitka HAUSNEROVÁ and Vít WEINBERGER. Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis? \textit{Cancers}. Basel: MDPI, 2022, vol.~14, No~1, p.~1-11. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers14010115.

Detailed Information on Publication Record